Novasep has announced the appointment of Christian Thiry as Chief Financial Officer.
The appointment follows that of Michel Spagnol as President and CEO of the company in June 2013 and further strengthens Novasep’s senior management team.
An MBA graduate from ESSEC (Paris), Christian Thiry joins Novasep following a 30-year career in audit and finance executive management in the life sciences field.
For the last 12 years he served as CFO and group executive committee member of Stallergenes, a Euronext listed biopharmaceutical company, where Christian helped expand the company’s business and grow its market capitalization whilst increasing profits.
“I am delighted to welcome Christian to Novasep’s executive team. This is a key appointment for Novasep as we continue to strengthen our core team which will be critical to driving our future growth,” said Michel Spagnol, CEO, Novasep.
Spagnol continued, “Christian’s broad experience is a major addition to the management team”. We would also like to thank Helen Lee Bouygues for her work as interim CFO to date and her continued support of the company during transition.”
“With a leadership in purification technologies combined with global contract manufacturing service capabilities, I believe that Novasep is uniquely positioned to capture new development opportunities,” said Christian Thiry, CFO, Novasep.
Thiry continued, “I am excited about adding my experience to Michel Spagnol and the senior management team in order to steer Novasep’s growth while increasing its profitability and strengthening its financial structure.”
In recent months, Novasep’s growth has gained momentum with significant new investments in Mourenx, France, to build the world’s largest chromatography plant dedicated to the pharmaceutical industry; in Le Mans, France, to expand manufacturing capabilities of cutting-edge anti-cancer therapies and in Shanghai, China, to better serve its clients in Asia.